|
 |
REVIEW ARTICLE |
|
Year : 2019 | Volume
: 11
| Issue : 5 | Page : 185-188 |
|
|
What's new in the pathophysiology of alopecia areata? the possible contribution of skin and gut microbiome in the pathogenesis of alopecia – Big opportunities, big challenges, and novel perspectives
Kamila Migacz-Gruszka1, Wojciech Branicki2, Aleksander Obtulowicz1, Magdalena Pirowska1, Krystian Gruszka3, Anna Wojas-Pelc1
1 Department of Dermatology, Jagiellonian University Medical College, Cracow, Poland 2 Malopolska Centre of Biotechnology, Jagiellonian University, Cracow, Poland 3 Department of Cardiology, Interventional Electrocardiology and Arterial Hypertension, Jagiellonian University Medical College, Cracow, Poland
Date of Web Publication | 16-Oct-2019 |
Correspondence Address: Dr Kamila Migacz-Gruszka Department of Dermatology, Jagiellonian University Medical College, 8 Skawinska Street, 31-066 Cracow Poland
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijt.ijt_76_19
Abstract | | |
The term “microbiome” defines the collective genome of all commensal, symbiotic, and pathogenic microbes living in the human body. The composition of microbiota in the gut and skin is influenced by many factors such as the stage of life, nutrition, lifestyle, and gender. In the past few years, several scientific papers have demonstrated an implication of microbiota in many immune-mediated diseases, for example, diabetes, ulcerative colitis, and multiple sclerosis. The alterations in the proportion of gut microbiota have emerged as potential immunomodulators with the capacity to induce physiologic as well as pathologic immune responses against the human body, causing inflammation and destruction of tissues or organs. The microbiota influences the differentiation of adaptive immune cells not only in the gut but also in the skin. Alopecia areata (AA) is a dermatologic disorder which causes hair loss in most cases resistant to treatment. There are some clinical and experimental evidences indicating that AA is the demonstration of autoimmune attack against hair follicles. The factors that may implicate such an autoimmunity in AA still remain unknown. Despite more and more evidences demonstrate that human microbiome plays a key role in human health and diseases, to the best of our knowledge, no study has been conducted to analyze an implication of microbiome in the pathogenesis of AA. Undoubtedly, there is a need to performing a study which might explain the involvement of gut and skin microbiota in the unclear pathogenesis of AA and lead to alternative treatment options for numerous patients suffering from current treatment limitations.
Keywords: Alopecia areata, dermatology, gut microbiome, pathophysiology, skin microbiome
How to cite this article: Migacz-Gruszka K, Branicki W, Obtulowicz A, Pirowska M, Gruszka K, Wojas-Pelc A. What's new in the pathophysiology of alopecia areata? the possible contribution of skin and gut microbiome in the pathogenesis of alopecia – Big opportunities, big challenges, and novel perspectives. Int J Trichol 2019;11:185-8 |
How to cite this URL: Migacz-Gruszka K, Branicki W, Obtulowicz A, Pirowska M, Gruszka K, Wojas-Pelc A. What's new in the pathophysiology of alopecia areata? the possible contribution of skin and gut microbiome in the pathogenesis of alopecia – Big opportunities, big challenges, and novel perspectives. Int J Trichol [serial online] 2019 [cited 2023 Mar 22];11:185-8. Available from: https://www.ijtrichology.com/text.asp?2019/11/5/185/269362 |
Introduction | |  |
The term “microbiome” defines the collective genome of all commensal, symbiotic, and pathogenic microbes living in the human body. The healthy intestinal and skin microbiota is an ecological community of trillions of microorganisms containing viruses, bacteria, archaea, and fungi that share human body space.[1],[2] Among them are not only commensal and symbiotic organisms occurring on the skin, mouth, gastrointestinal tract, and in the respiratory and urinary tracts but also those that cause pathological conditions. The composition of microbiota in the gut and skin is influenced by many factors such as the stage of life, nutrition, lifestyle, and gender.[3]
Gut Microbiota and Immune System | |  |
In the past few years, several scientific papers have demonstrated an implication of microbiota in many immune-mediated diseases, for example, diabetes, Crohn's disease, ulcerative colitis, and multiple sclerosis. The interpretation and exploration of such findings occurring in many studies published recently are a subject of much debate now. The prevalence of autoimmune diseases is growing, especially in Western countries, affecting majorly women.[4],[5] It has been considered that modern era lifestyle can influence the normal flora composition effecting in deregulation of the immune system. The alterations in the proportion of gut microbiota have emerged as potential immunomodulators with the capacity to induce physiologic as well as pathologic immune responses against the human body, causing inflammation and destruction of tissues or organs. Imbalances in the gut microbiota, described as dysbiosis, may trigger several disorders through the manipulation of activity of T-cells that are both near to and distant from the site of their induction.[6] Particular bacteria inhabiting defined niches transmit distinct signals and may affect functions of innate and adaptive immune system. Thus microbiome may effect in distal to the site of colonization systemic process. Culturing and characterization of human commensal bacteria gave the possibility to assess their influence on the host's immune system as well as provide new tools for defining which cell types and signaling tracks are relevant for inducing of the distinct immune responses. A valuable advance was the identification of immunoglobulin A (IgA)-coated gut bacteria in humans, which provides an idea of the bacteria that can be sensed by the cells of the adaptive immune system. This investigation enables a comparison of species of bacteria that elicit T-cell-dependent and T-cell-independent IgA-mediated responses in the host's immune system.[7],[8],[9] Mucosal IgA is secreted across the epithelium which binds to the immunoglobulin receptor. IgA can bind to microbes, several components of diet or antigens in the lumen of the intestine. As the result of this process is a formation of IgA-coated elements which prevent direct interaction with host's immune system. Thus, it controls the genes' expression by intestinal microbes as well as it can provide a physical barrier. Notably, gut microbiome affects the accumulation of cells that may express IgA and both the level and the diversity of IgA in the lumen.[3]
Skin Microbiota and Immune System | |  |
The microbiota influences the differentiation of adaptive immune cells not only in the gut but also in the skin. Although immunological communication occurs between mucosal tissues such as the intestine and the lung or the nasopharynx, it seems to be specific for compartment immunological regulation in the skin.[8],[9],[10] A study suggested that Th17 cells in the skin are affected by the skin microbiota independently of gut microbiota. The production of interleukin (IL)-17A by T-cells in the skin requires the expression of IL1R but not IL23R, in contrast to the requirements of Th17 cells in the gut and in line with compartment-specific mechanism for T-cell regulation. This condition might be caused by different types of challenges that skin and mucosal sites are faced with, which effect in the requirement of distinct pathways to control their local immune responses.[11],[12],[13]
Gut–skin Axis? | |  |
On the other hand, some studies suggest that the intestinal microbiome's influence extends beyond the gut and thus contributes to the function and dysfunction of distant organ system.[12] In this ever-expanding field, scientists are exploring how the local microbiome influences immunity at distal sites such as skin, clarifying the existence of “gut–skin axis.”[14],[15] It is still undiscovered whether the altered composition of gut microbiota may precede the development of the skin disease, and thereby shift the immune system, disrupting the gut epithelial barrier. On the other hand, it has been considered whether skin and gut microbiome are autonomous and independent from each other. Skin as a physical barrier constantly interacting with external factors such as solar irradiation, grades of humidity or dryness, and microorganisms might influence integrity, homeostasis, and the composition of skin microbiota.[13] These factors may lead to the skin dysbiosis and thus contribute to the disruption of immune homeostasis in the skin and promote the development of diverse skin diseases regardless of gut microbiome.
Complex and Unexplored Pathophysiology of Alopecia Areata and New Perspectives | |  |
Alopecia areata (AA) is a dermatologic disorder occurring in the population at a frequency of 0.1%–0.2%, which causes hair loss in most cases resistant to treatment. The disease negatively influences the shaping of the body's image and self-esteem, which makes an important role in the process of socialization, causing in many cases inefficient functioning in the social environment and decreased quality of life.[16] The etiology and precise pathomechanism of AA is speculative [Table 1]. There are some clinical and experimental evidences indicating that AA is the demonstration of autoimmune attack against hair follicles which causes an inflammatory condition of the hair follicle.[17],[18] The autoimmunity is the defect in immune tolerance, resulting in the production and proliferation of autoreactive T-cells and antibodies. The factors that may implicate such an autoimmunity in AA, however, remain still unknown.[19],[20] Despite more and more evidences demonstrate that human microbiome plays a key role in human health and diseases, to the best of our knowledge, no study has been conducted to analyze an implication of microbiome in the pathogenesis of AA. There is only one case report describing hair growth in two patients suffering from AA after fecal microbiota transplant, which may suggest the potential role of gut microbiota in the disease mechanism.[21] Undoubtedly, there is a need to performing a study which might explain the involvement of gut and skin microbiota in the unclear pathogenesis of AA, which leads to alternative treatment options for numerous patients suffering from current treatment limitations [Figure 1]. Simultaneous analysis of both gut and skin microbiome in patients with AA will provide an exceptional insight if observed autoimmunity in AA is caused from the “inside” (gut–skin axis) or from the “outside” (skin). | Figure 1: What's new in etiopathology of alopecia areata – possible role of skin and gut microbiome
Click here to view |
Conclusion | |  |
The proper understanding of the role of skin and gut microbiome might be undoubtedly a novel insight at the still unexplored pathophysiology of AA. Explanation of mechanisms that distinguish between physiologic and pathogenic microbiome–host interactions might identify therapeutic targets for preventing or modulating that disease. Therapeutic microbiome manipulation might represent an innovative treatment option for AA and undoubtedly has to be an important subject for future research regarding the important role of these dermatologic diseaseS in the abnormal process of socialization, decreasing the quality of life.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References | |  |
1. | Human Microbiome Project Consortium. A framework for human microbiome research. Nature 2012;486:215-21. |
2. | Sommer F, Bäckhed F. The gut microbiota – Masters of host development and physiology. Nat Rev Microbiol 2013;11:227-38. |
3. | Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature 2016;535:75-84. |
4. | Bengmark S. Gut microbiota, immune development and function. Pharmacol Res 2013;69:87-113. |
5. | Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes 2012;3:4-14. |
6. | Peterson CT, Sharma V, Elmén L, Peterson SN. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin Exp Immunol 2015;179:363-77. |
7. | Palm NW, de Zoete MR, Cullen TW, Barry NA, Stefanowski J, Hao L, et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 2014;158:1000-10. |
8. | Bunker JJ, Flynn TM, Koval JC, Shaw DG, Meisel M, McDonald BD, et al. Innate and adaptive humoral responses coat distinct commensal bacteria with immunoglobulin A. Immunity 2015;43:541-53. |
9. | Öhman L, Törnblom H, Simrén M. Crosstalk at the mucosal border: Importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol 2015;12:36-49. |
10. | Berbers RM, Nierkens S, van Laar JM, Bogaert D, Leavis HL. Microbial dysbiosis in common variable immune deficiencies: Evidence, causes, and consequences. Trends Immunol 2017;38:206-16. |
11. | Nagy G, Huszthy PC, Fossum E, Konttinen Y, Nakken B, Szodoray P. Selected aspects in the pathogenesis of autoimmune diseases. Mediators Inflamm 2015;2015:351732. |
12. | Salem I, Ramser A, Isham N, Ghannoum MA. The gut microbiome as a major regulator of the gut-skin axis. Front Microbiol 2018;9:1459. |
13. | Lee SY, Lee E, Park YM, Hong SJ. Microbiome in the gut-skin axis in atopic dermatitis. Allergy Asthma Immunol Res 2018;10:354-62. |
14. | Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller W, et al. Compartmentalized control of skin immunity by resident commensals. Science 2012;337:1115-9. |
15. | Borde A, Šstrand A. Alopecia areata and the gut-the link opens up for novel therapeutic interventions. Expert Opin Ther Targets 2018;22:503-11. |
16. | Wang ECE, Christiano AM. The changing landscape of alopecia areata: The translational landscape. Adv Ther 2017;34:1586-93. |
17. | Pratt CH, King LE Jr. Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers 2017;3:17011. |
18. | Dainichi T, Kabashima K. Alopecia areata: What's new in epidemiology, pathogenesis, diagnosis, and therapeutic options? J Dermatol Sci 2017;86:3-12. |
19. | Juárez-Rendón KJ, Rivera Sánchez G, Reyes-López MÁ, García-Ortiz JE, Bocanegra-García V, Guardiola-Avila I, et al. Alopecia areata. Current situation and perspectives. Arch Argent Pediatr 2017;115:e404-e411. |
20. | Ito T, Tokura Y. The role of cytokines and chemokines in the T-cell-mediated autoimmune process in alopecia areata. Exp Dermatol 2014;23:787-91. |
21. | Rebello D, Wang E, Yen E, Lio PA, Kelly CR. Hair growth in two alopecia patients after fecal microbiota transplant. ACG Case Rep J 2017;4:e107. |
22. | Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 2018;78:1-2. |
23. | Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014;20:1043-9. |
24. | Betz RC, Petukhova L, Ripke S, Huang H, Menelaou A, Redler S, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun 2015;6:5966. |
25. | Redler S, Angisch M, Heilmann S, Wolf S, Barth S, Basmanav BF, et al. Immunochip-based analysis: High-density genotyping of immune-related loci sheds further light on the autoimmune genetic architecture of alopecia areata. J Invest Dermatol 2015;135:919-21. |
26. | Jagielska D, Redler S, Brockschmidt FF, Herold C, Pasternack SM, Garcia Bartels N, et al. Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. J Invest Dermatol 2012;132:2192-7. |
27. | Zhang X, Yu M, Yu W, Weinberg J, Shapiro J, McElwee KJ. Development of alopecia areata is associated with higher central and peripheral hypothalamic-pituitary-adrenal tone in the skin graft induced C3H/HeJ mouse model. J Invest Dermatol 2009;129:1527-38. |
28. | Willemsen R, Vanderlinden J, Roseeuw D, Haentjens P. Increased history of childhood and lifetime traumatic events among adults with alopecia areata. J Am Acad Dermatol 2009;60:388-93. |
29. | McElwee KJ, Niiyama S, Freyschmidt-Paul P, Wenzel E, Kissling S, Sundberg JP, et al. Dietary soy oil content and soy-derived phytoestrogen genistein increase resistance to alopecia areata onset in C3H/HeJ mice. Exp Dermatol 2003;12:30-6. |
[Figure 1]
[Table 1]
This article has been cited by | 1 |
Claudin-3 is a novel intestinal integrity marker in patients with alopecia areata: Correlation with the disease severity |
|
| Dina Rafik, Ihab Younis, Rana Atef, Hanaa Eid | | Journal of Cosmetic Dermatology. 2023; | | [Pubmed] | [DOI] | | 2 |
Microbiota dysbiosis and myasthenia gravis: Do all roads lead to Rome? |
|
| Bhupinder Kapoor, Monica Gulati, Reena Gupta, Rajeev K. Singla | | Autoimmunity Reviews. 2023; 22(5): 103313 | | [Pubmed] | [DOI] | | 3 |
Stratification of alopecia areata reveals involvement of CD4 T cell populations and altered faecal microbiota |
|
| K A Bain, B Nichols, F Moffat, C Kerbiriou, U Z Ijaz, K Gerasimidis, I B McInnes, A Åstrand, S Holmes, S W F Milling | | Clinical and Experimental Immunology. 2022; | | [Pubmed] | [DOI] | | 4 |
Physiotherapeutic methods in the complex treatment of alopecia |
|
| Vera Vasilievna Kiryanova, Yulia Sergeevna Egorova , Elena Vadimovna Petrova, Alla Askoldovna Potapchuk , Antonina Anatolievna Chaban | | Fizioterapevt (Physiotherapist). 2022; (01): 68 | | [Pubmed] | [DOI] | | 5 |
The Human Skin Microbiome in Selected Cutaneous Diseases |
|
| Silvia Carmona-Cruz, Luz Orozco-Covarrubias, Marimar Sáez-de-Ocariz | | Frontiers in Cellular and Infection Microbiology. 2022; 12 | | [Pubmed] | [DOI] | | 6 |
The gut microbiome and Alopecia areata: Implications for early diagnostic biomarkers and novel therapies |
|
| Yongbo Kang, Yue Cai, Yanqin Zhao, Ying Yang | | Frontiers in Nutrition. 2022; 9 | | [Pubmed] | [DOI] | | 7 |
Clinical Translation of Microbiome Research in Alopecia Areata: A New Perspective? |
|
| Fabio Rinaldi, Anna Trink, Angela Papale, Giammaria Giuliani, Daniela Pinto | | Cosmetics. 2022; 9(3): 55 | | [Pubmed] | [DOI] | | 8 |
A Potential Predictive Role of the Scalp Microbiome Profiling in Patients with Alopecia Areata: Staphylococcus caprae, Corynebacterium, and Cutibacterium Species |
|
| Eun Jeong Won, Hyun Hee Jang, Hansoo Park, Seong Jin Kim | | Microorganisms. 2022; 10(5): 864 | | [Pubmed] | [DOI] | | 9 |
Hydra
and the hair follicle – An unconventional comparative biology approach to exploring the human holobiont
|
|
| Marta B. Lousada, Tim Lachnit, Janin Edelkamp, Ralf Paus, Thomas C. G. Bosch | | BioEssays. 2022; : 2100233 | | [Pubmed] | [DOI] | | 10 |
Alopecia areata mit gutem Ansprechen auf Tofacitinib |
|
| A. Maksimow, D. Stintzing, J. Wohlrab | | Der Hautarzt. 2021; 72(6): 525 | | [Pubmed] | [DOI] | | 11 |
Alopecia y microbioma: ¿futura diana terapéutica? |
|
| D. Barquero-Orias, O. Muñoz Moreno-Arrones, S. Vañó-Galván | | Actas Dermo-Sifiliográficas. 2021; 112(6): 495 | | [Pubmed] | [DOI] | | 12 |
Alopecia and the Microbiome: A Future Therapeutic Target? |
|
| D. Barquero-Orias, O. Muñoz Moreno-Arrones, S. Vañó-Galván | | Actas Dermo-Sifiliográficas (English Edition). 2021; 112(6): 495 | | [Pubmed] | [DOI] | | 13 |
Gut–Skin Axis: Current Knowledge of the Interrelationship between Microbial Dysbiosis and Skin Conditions |
|
| Britta De Pessemier, Lynda Grine, Melanie Debaere, Aglaya Maes, Bernhard Paetzold, Chris Callewaert | | Microorganisms. 2021; 9(2): 353 | | [Pubmed] | [DOI] | | 14 |
Current controversies in trichology: a European expert consensus statement |
|
| T. Meyer-Gonzalez, D. Bacqueville, R. Grimalt, V. Mengeaud, B.M. Piraccini, L. Rudnicka, D. Saceda-Corralo, A. Vogt, S. Vano-Galvan | | Journal of the European Academy of Dermatology and Venereology. 2021; 35(S2): 3 | | [Pubmed] | [DOI] | | 15 |
Efficacy of Postbiotics in a PRP-Like Cosmetic Product for the Treatment of Alopecia Area Celsi: A Randomized Double-Blinded Parallel-Group Study |
|
| Fabio Rinaldi, Anna Trink, Daniela Pinto | | Dermatology and Therapy. 2020; 10(3): 483 | | [Pubmed] | [DOI] | |
|
 |
 |
|